Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MDCX

Medicus Pharma Ltd

Apr 02 • 04:00PM ET

3.40

Dollar change -0.56
Percentage change -14.14	%

Healthcare • Biotechnology • Canada • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	77.42%	Shs Outstand	11.82M	Perf Week	1.19%
Market Cap	40.19M	Forward P/E	-	EPS next Y	-1.53	Insider Trans	0.00%	Shs Float	2.67M	Perf Month	17.24%
Income	-11.16M	PEG	-	EPS next Q	-	Inst Own	12.72%	Short Float	2.79%	Perf Quarter	30.77%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	1.49	Perf Half Y	-
Book/sh	0.27	P/B	12.82	EPS next Y	-	ROA	-295.90%	Short Interest	0.07M	Perf Year	-
Cash/sh	0.35	P/C	9.66	EPS next 5Y	19.09%	ROE	-525.44%	52W Range	1.80 - 6.00	Perf YTD	39.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-333.93%	52W High	-43.33%	Beta	-
Dividend TTM	-	Quick Ratio	2.33	Sales past 5Y	0.00%	Gross Margin	-	52W Low	88.89%	ATR (14)	0.53
Dividend Ex-Date	-	Current Ratio	2.33	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	50.73	Volatility	18.45% 18.60%
Employees	12	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	11.00
Option/Short	No / No	LT Debt/Eq	0.07	EPS Q/Q	38.85%	Payout	-	Rel Volume	2.48	Prev Close	3.96
Sales Surprise	-	EPS Surprise	-27.07%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	49.96K	Price	3.40
SMA20	4.00%	SMA50	4.64%	SMA200	7.00%	Trades		Volume	123,975	Change	-14.14%

Mar-10-25 04:05PM	Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering (Newsfile) +11.48% -23.24%
Mar-06-25 08:30PM	Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering (Newsfile)
07:30AM	Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (Newsfile)
Feb-27-25 07:30AM	Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (GlobeNewswire) +12.16%
Feb-14-25 07:30AM	Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) (GlobeNewswire) +19.48%
07:41AM	Loading…
Feb-11-25 07:41AM	Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV) (Newsfile)
Dec-12-24 07:30AM	Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch (GlobeNewswire)
Dec-02-24 07:30AM	Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region (GlobeNewswire) -8.72%
Nov-18-24 07:30AM	Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer (Newsfile) -6.70%
Nov-15-24 04:47PM	Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States (Newsfile) -15.47%

Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company, which engages in investing in novel life sciences and bio-technology companies. It focuses on identifying, acquiring, and advancing relatively de-risked clinical stage assets through clinical development and commercialization. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDCX

Medicus Pharma Ltd

Upgrade your FINVIZ experience